Standout Papers

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With... 2002 2026 2010 2018 2.1k
  1. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer (2008)
    Cornelia Liedtke, Chafika Mazouni et al. Journal of Clinical Oncology
  2. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer (2019)
    Fabrice André, Eva Ciruelos et al. New England Journal of Medicine
  3. DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy (2006)
    Ken A. Olaussen, Ariane Dunant et al. New England Journal of Medicine
  4. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer (2015)
    Nicholas C. Turner, Jungsil Ro et al. New England Journal of Medicine
  5. Malignant effusions and immunogenic tumour-derived exosomes (2002)
    Fabrice André, Noël E.C. Schartz et al. The Lancet
  6. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018)
    Nicholas C. Turner, Dennis J. Slamon et al. New England Journal of Medicine
  7. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach (2019)
    Claudio Luchini, Frédéric Bibeau et al. Annals of Oncology
  8. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline (2016)
    Lyndsay N. Harris, Nofisat Ismaila et al. Journal of Clinical Oncology
  9. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer (2016)
    Charlotte Fribbens, Ben O’Leary et al. Journal of Clinical Oncology
  10. Dendritic cell–derived exosomes for cancer therapy (2016)
    Jonathan M. Pitt, Fabrice André et al. Journal of Clinical Investigation
  11. HER2-Low Breast Cancer: Pathological and Clinical Landscape (2020)
    Paolo Tarantino, Erika Hamilton et al. Journal of Clinical Oncology
  12. The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial (2018)
    Ben O’Leary, Rosalind Cutts et al. Cancer Discovery
  13. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) (2018)
    Joaquı́n Mateo, Debyani Chakravarty et al. Annals of Oncology
  14. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 (2020)
    Fabrice André, Eva Ciruelos et al. Annals of Oncology
  15. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial (2021)
    Eric P. Winer, Seock‐Ah Im et al. The Lancet Oncology
  16. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future (2020)
    Laura M. Spring, Seth A. Wander et al. The Lancet
  17. PI3K inhibitors are finally coming of age (2021)
    Bart Vanhaesebroeck, Matthew W. D. Perry et al. Nature Reviews Drug Discovery
  18. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer (2019)
    Nicholas C. Turner, Yuan Liu et al. Journal of Clinical Oncology
  19. Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies (2021)
    Mihaela Aldea, Fabrice André et al. Cancer Discovery
  20. Delivering precision oncology to patients with cancer (2022)
    Joaquı́n Mateo, Lotte Steuten et al. Nature Medicine
  21. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment (2024)
    Antonio Passaro, Maise Al Bakir et al. Cell
  22. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study (2022)
    Massimo Cristofanilli, Hope S. Rugo et al. Clinical Cancer Research

Immediate Impact

6 by Nobel laureates 19 from Science/Nature 138 standout
Sub-graph 1 of 17

Citing Papers

From geroscience to precision geromedicine: Understanding and managing aging
2025 Standout
Theranostic Fluorescent Probes
2024 Standout

Works of Fabrice André being referenced

Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision?
2023
Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
2013

Author Peers

Author Last Decade Papers Cites
Fabrice André 19923 12659 13758 13587 667 36.8k
Massimo Cristofanilli 25726 11443 18181 9603 589 37.3k
Hope S. Rugo 30324 15990 11168 10917 833 43.5k
Isaiah J. Fidler 20990 7977 13490 21725 496 47.8k
Martine Piccart 26838 9035 16098 12544 830 41.8k
Sherene Loi 23358 10545 10766 9230 443 33.6k
Jean‐Charles Soria 19265 12561 6724 12792 675 34.0k
Seock‐Ah Im 23147 13475 8677 7039 652 31.7k
Kenneth J. Pienta 17615 17167 11891 21478 662 48.6k
Robert S. Kerbel 16351 5745 13246 24243 398 41.1k
Ming‐Sound Tsao 14968 13475 8193 16214 644 36.3k

All Works

Loading papers...

Rankless by CCL
2026